clinical trial · NCT05307705
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Eli Lilly and Company·phase1·active not recruiting·n = 193
Breast CancerLOXO-783FulvestrantImlunestrantAbemaciclibAnastrozole, Exemestane, or LetrozolePaclitaxel
brief summary
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse.
started
May 11, 2022
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Apr 20, 2026
official title
A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol